CoChat
Sign Up
Cited by 1,063COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Clinical Features of 69 Cases With Coronavirus Disease 2019 in Wuhan, China

Open access
Wang, Zhongliang, Yang, Bohan, Li, Qianwen, Wen, Lu, Zhang, Ruiguang·2020·Clinical Infectious Diseases
DOI 10.1093/cid/ciaa272PMC PMC7184452
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: From December 2019 to February 2020, 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a serious outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China. Related clinical features are needed. Methods: We reviewed 69 patients who were hospitalized in Union hospital in Wuhan between 16 January and 29 January 2020. All patients were confirmed to be infected with SARS-CoV-2, and the final date of follow-up was 4 February 2020. Results: The median age of 69 enrolled patients was 42.0 years (interquartile range 35.0–62.0), and 32 patients (46%) were men. The most common symptoms were fever (60 [87%]), cough (38 [55%]), and fatigue (29 [42%]). Most patients received antiviral therapy (66 [98.5%] of 67 patients) and antibiotic therapy (66 [98.5%] of 67 patients). As of 4 February 2020, 18 (26.9%) of 67 patients had been discharged, and 5 patients had died, with a mortality rate of 7.5%. According to the lowest SpO2 during admission, cases were divided into the SpO2 ≥ 90% group (n = 55) and the SpO2 < 90% group (n = 14). All 5 deaths occurred in the SpO2 < 90% group. Compared with SpO2 ≥ 90% group, patients of the SpO2 < 90% group were older and showed more comorbidities and higher plasma levels of interleukin (IL) 6, IL10, lactate dehydrogenase, and C reactive protein. Arbidol treatment showed tendency to improve the discharging rate and decrease the mortality rate. Conclusions: COVID-19 appears to show frequent fever, dry cough, and increase of inflammatory cytokines, and induced a mortality rate of 7.5%. Older patients or those with underlying comorbidities are at higher risk of death.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciaa272

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 2

  1. National Health Commission of China, Guideline of management of COVID-19 (version 3)
  2. National Health Commission of China, Guideline of management of COVID-19 (version 7)

Cited by

Sorted by citations

Items 901–1,000 of 1,001

Related

See all

Metadata

Authors
Wang, Z., Yang, B., Li, Q., Wen, L., & Zhang, R.
Affiliations
  • Wuhan Union Hospital (CN)
  • Huazhong University of Science and Technology (CN)
Corresponding author
Zhang, Ruiguang
ORCID
Venue
Clinical Infectious Diseases
Publisher
Oxford University Press (OUP)
Published
2020-03-16
Volume
71
Issue
15
Pages
769-777
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
DOI
10.1093/cid/ciaa272
PMC
PMC7184452
OpenAlex
W3012492786
Cited by
1,063
References
28
Citations by year
2026: 3 · 2025: 10 · 2024: 32 · 2023: 92 · 2022: 120 · 2021: 288 · 2020: 516
FWCI
33.33
Type
journal article
Language
en
Open access
Licence
academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
Locations
  • Clinical Infectious Diseases (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Clinical Neurology › Long-Term Effects of COVID-19
Keywords
COVID-19 pandemic, SARS-CoV-2, clinical features, mortality, oxygen saturation, comorbidities, inflammatory cytokines, interleukin-6, IL-10, C-reactive protein, lactate dehydrogenase, arbidol, antiviral therapy, hospitalized patients
MeSH terms
Betacoronavirus, COVID-19, SARS-CoV-2, Adult, Aged, C-Reactive Protein, China, Cough, Female, Fever, Hospitalization, Humans, Male, Middle Aged, Patient Discharge, Pneumonia, Viral, Interleukin-6, Interleukin-10, Coronavirus Infections, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review